Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manjunath P Pai

Showing results (111-120 of 184) with videos related to

Pageof 19
Sort By:
Antimicrobial Agents and Chemotherapy|June 15, 2011
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein bindingJill M Butterfield, Nimish Patel, Manjunath P Pai, et al.
Current Medical Research and Opinion|May 24, 2007
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysisHua Chen, Katie J Suda, Robin S Turpin, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2025
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?Manjunath P Pai, Pier Giorgio Cojutti, Milo Gatti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2002
Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faeciumManjunath P Pai, Keith A Rodvold, Paul C Schreckenberger, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2025
Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusionPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.
Clinical and Translational Science|November 19, 2024
High-dose intranasal insulin in an adaptive dose-escalation study in healthy human participantsFlorian Schmitzberger, Jennifer Fowler, Cindy H Hsu, et al.
Clinical Pharmacology and Therapeutics|June 11, 2026
Toward the Future: A Race-Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug DosingMarc H Scheetz, Thomas P Lodise, Nathaniel J Rhodes, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2018
Validation of Heel Stick Microsampling To Optimize Micafungin Doses in Neonates and Young InfantsCinzia Auriti, Bianca Maria Goffredo, Maria Paola Ronchetti, et al.
Regulatory Toxicology and Pharmacology : RTP|June 2, 2018
In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulationsAmy Barton Pai, Manjunath P Pai, Dan E Meyer, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2018
Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult SubjectsKristen L Bunnell, Manjunath P Pai, Monica Sikka, et al.
Pageof 19

Showing results (111-120 of 184) with videos related to

Sort By:
Pageof 19
Antimicrobial Agents and Chemotherapy|June 15, 2011
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein bindingJill M Butterfield, Nimish Patel, Manjunath P Pai, et al.
Current Medical Research and Opinion|May 24, 2007
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysisHua Chen, Katie J Suda, Robin S Turpin, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2025
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?Manjunath P Pai, Pier Giorgio Cojutti, Milo Gatti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2002
Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faeciumManjunath P Pai, Keith A Rodvold, Paul C Schreckenberger, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2025
Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusionPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.
Clinical and Translational Science|November 19, 2024
High-dose intranasal insulin in an adaptive dose-escalation study in healthy human participantsFlorian Schmitzberger, Jennifer Fowler, Cindy H Hsu, et al.
Clinical Pharmacology and Therapeutics|June 11, 2026
Toward the Future: A Race-Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug DosingMarc H Scheetz, Thomas P Lodise, Nathaniel J Rhodes, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2018
Validation of Heel Stick Microsampling To Optimize Micafungin Doses in Neonates and Young InfantsCinzia Auriti, Bianca Maria Goffredo, Maria Paola Ronchetti, et al.
Regulatory Toxicology and Pharmacology : RTP|June 2, 2018
In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulationsAmy Barton Pai, Manjunath P Pai, Dan E Meyer, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2018
Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult SubjectsKristen L Bunnell, Manjunath P Pai, Monica Sikka, et al.
Pageof 19